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Summary.-In a longitudinal study of the evolution of serum p2-microglobulin
(p2-m) levels in 37 patients with myelomatosis, those patients with a level of <4 mg/l
at first presentation had a median survival of46 months, whereasthose with an initial
level of >4 mg/l had a median survival of 15 months. The p2-m appeared to be
independent of the level of the paraprotein and its class, as seen in a vertical study of
129 patients. Analysis of the influence of a rising serum creatinine on the serum
p2-im indicates that p2-rm production is excessive in advanced disease with or without
renal failure. Practical application of the measurement of serum p2-m in the strati-
fication and monitoring of patients is suggested.
SEVERAL INDICES have been proposed
for the clinical stratification of multiple
myelomatosis. The system devised by
Durie & Salmon (1975), using a panel of
clinical biochemical factors, has the advan-
tage of being correlated with survival and
predictive of the response to treatment.
Hence any new biochemical test, to be
considered seriously for the stratification
ofmultiple myelomatosis, must be capable
of providing information comparable to
the more complex systems in current use.
There is growing evidence that serum
P2-microglobulin (32-m) level is often
increased in multiple myelomatosis (Shus-
ter et al., 1976; Belleville etal., 1978). How-
ever, P2-m is a low-mol. wt. protein
(11,800 dalton) and its serum levels depend
on both its production and its renal clear-
ance. Elevation of serum /2-m occurs in
renal clearance. Elevation of serum :2-m
occurs in renal impairment (Revillard,
1979). As some form of renal involvement
will occur eventually in about half of the
patients with multiple myelomatosis (De-
Fronzo et al., 1978) it could be argued that
the measurement of serum /2-m is only
providing refined information about mul-
tiple myeloma that might be of particular
importance in patients with normal serum
creatinine, and may be a simple substitute
for the serial measurement of paraprotein
levels in the monitoring of multiple
myelomatosis.
PATIENTS AND METHODS
Two group of patients were studied; all
fulfilled the accepted criteria for the diagnosis
of myelomatosis (Chronic Leukaemia-Myelo-
ma Task Force, 1973). The first group (Group
1) comprised 36 patients with myelomatosis
attending the General Infirmary at Leeds
between 1975 and 1979. They included 21
males and 15 females with a median age of
62-8 years. The distribution ofthis population
according to their paraprotein class was IgG,
18; IgA, 9; IgD, 1; IgM, 1; light chains only
(Bence Jones protein), 7. Serum samples were
obtained sequentially in order to study the
evolution of /82-m concentration during the
disease. Patients were staged according to the
system of Durie & Salmon (1975). The sur-
vival probabilities were calculated by the
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method of Kaplan & Meier (1958) and the
significance between the survival of the sub-
sets calculated by the log-rank method (Peto
et al., 1977). Twenty-three of this group of
patients died during the period ofobservation.
The second group (Group II) comprised
129 patients with myelomatosis from whom
157 serum samples were referred to the
Supraregional Protein Reference Unit, Shef-
field, for measurement of paraprotein levels.
The sera were distributed at random at
various stages ofthe disease, and represented
a reference population in which the hypo-
theses suggested by the study of the first
group could be tested. Additional sera from
patients with renal impairment due to myelo-
matosis were examined to explore the rela-
tionship between serum creatinine and serum
/2-m in myelomatosis.
The serum /2-mn was measured by the
Phadebas radioimmunoassay (Pharmacia,
Uppsala, Sweden). The normal limits for this
assay in blood donors are 0 8-2-4 mg/l. C-
reactive protein was measured by radial
immunodiffusion, using antisera and stan-
dards obtained from the Behring Institut,
Marburg/Lahn, Germany. Serum levels > 10
mg/l were considered abnormal, but a dis-
criminant level of 20 mg/l was adopted as
being indicative of active infection. Serum
creatinine was measured by Jaffe's method:
a value of 140 HM wNas arbitrarily taken as the
upper limit of normal in this population. The
choice ofthe serum /2-m 4 mg/l cut-off as the
basis for stratification of the patients into
good and bad prognosis groups wAas made after
reference to results obtained in "normal"
subjects, over 60 years of age, AN-here the
median was 2-2 mg/l and range 1 2-40 mg/l
(Agerup, personal communication).
RESULTS
The general relationship between serum
/2-m level at first presentation and the
probability of survival in Group I, is
shown in Fig. 1. The population has been
arbitrarily divided into patients with an
initial serum /2-m >4 mg/l (n = 16) and
those with the level < 4 mg/l (n = 20); the
median survival of the 2 groups of
patients was 15 and 46 months, respec-
tively. The separation of the population
in this way was highly significant (P <
k
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FIG. 1. The survival probability according
to whether the serum f2-m was greater
(---) or less ( ) than 4 mg/l at first
presentation.
0-001) with respect to their relative sur-
vival.
Only 3 patients in this group presented
with a creatinine > 140 p,M, and their
characteristics were as follows: Bence
Jones K, serum :2-m, 3*9 mg/l; crea-
tinine, 165 tuM, with a survival of 48
months; IgG K, serum /2-m, 17.7 mg/l;
creatinine, 319 LM, with a survival of 2
months; and IgG K, serum /2-m, 14*0
mg/l; creatinine, 173 ELM, with a survival
of 9 months. On the other hand a further
5 of these patients developed renal failure
during the course of their illness, in 3 of
whom it was a brief terminal event.
The relationship of serum /2-m to the
estimate of tumour mass is shown in
Table I. This population was also divided
into those who died within 24 months of
presentation and those who survived
beyond 24 months. The changes in serum
/2-m levels that occurred during the
evolution of their disease are illustrated in
Figs. 2 and 3 respectively. At one year
after presentation, 13 patients had a
TABLE I. Relation of clinical estimate of
tumour mass (Durie & Salmon) to
serutm :2-m level
Tumour mass
Number
Serum ,82-m (mg/l) at
presentation
(Mean +s.d.)
Inter-
Low mediate High
8 13 9
2-48 3-98 10-2
0-87 1*97 5.10
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FIG. 2.-Evolution of serum f2-m in patients who died within 24 months ofpresentation.
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FIG. 3.-Evolution of serum ,82-m in patients who survived 40 or more months.
serum f2-m <4 mg/l; and 11 >4 mg/l;
the median survival after this time was
> 12 and 6 months respectively.
The distribution of serum P2-m levels in
Group II is demonstrated in Table II,
which shows the range of paraprotein
levels encountered in patients with normal
serum P2-m levels, those with moderately
raised serum P2-m (3 6 mg/l) and those
with marked elevation (> 6 mg/l), as well
as the incidence of raised C-reactive pro-
tein and raised serum creatinine for each
class ofparaprotein.
The correlation between sequential
changes in the P2-m and paraprotein
levels was examined in 8 patients with at
least 7 pairs of values per patient. The
Spearman rank test showed that in only 2
patients were the levels of these serum
proteins significantly correlated. In Group
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TABLE II.-Cross-sectional study ofpatients in Group II
Serum ,2-m(mg/1)
Ig class
T_ lgG A n
median (g/l)
range
IgGK n
median (g/l)
range
IgAK n
median (g/l)
range
IgA A n
median (g/l)
range
ns only n
Total No.
0-2 9 3-6
14 19
18 25
5-38 2-49
30 18
9 16
1-34 1-41
6 16
16 22
1-19 2-64
8 7
11 15
4-19 6-22
1 4
59 64
>6
16
35
1-48
4
27
1-87
6
32
17-43
4
44
23-96
4
34
Creatinine
> 140pM
8
C-reactive
protein
> 20 mg/l (%)
4/49 (8.2)
1 7/52 (13-5)
2 1/28 (3.6)
1 3/19 (15.8)
6
18
0/9 (0)
15/157
II, for patients within the same protein
class (e.g. IgG) there was no significant
correlation.
The relation of serum f2-m levels and
creatinine levels in patients in whom renal
impairment is indicated by elevated
creatinine, is shown in Fig. 4, where com-
parison is made with the regression slopes
for these variates in chronic renal failure
and systemic lupus erythematosus, as
published by Hall (1979). It will be seen
that there is a wide range of serum ,82-m
levels for a particular creatinine level. The
correlation coefficient, as measured by the
Spearman ranking test, was r =0-61,
P = 0.01. In the longitudinal studies, levels
of serum ,B2-m > 15 mg/l were always
associated with creatinine > 140 ,uM. But
considerable change in serum ,82-m levels,
either downwards during the reduction of
the larger tumour burdens or upwards as
the mass expanded, could occur without a
coincidental change in serum creatinine.
DISCUSSION
The discriminant power of serum ,B2-m
level of 4 mg/l is apparent from the sur-
vival studies (Fig. 1) where good and bad
prognostic groups are distinguished. It
will require a larger series to define the
level for optimal separation of these 2
groups. There is also a clear relation
between serum /2-m levels and estimates
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FIG. 4.-Serum ,2-m levels in patients with
elevated serum creatinine. The regression
line for systemic lupus erythematosus
(SLE) and chronic renal failure are from
Hall (1979).
of tumour mass, using the system devised
by Durie & Salmon (Table I). On the other
hand, the level of serum /32-m does not
Light chair
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correlate with the amount of paraprotein
in the blood, whatever its class. The serum
,B2-m level may follow the paraprotein
level within a given patient, but this
correlation is not seen when many patients
are considered collectively, or when they
are subdivided according to their para-
protein class.
At present it is uncertain what is the
source of the raised serum 32-m in
myelomatosis where frank renal failure
has not supervened. Excessive production
and abnormal P2-m elimination by the
kidney could both be contributory factors.
Once the creatinine begins to rise, the
effect of hyperproduction is magnified and
the serum /2-m is elevated more than is
usual for chronic renal disease. Assuming
that the raised levels are due to excess
production, it is not known whether this
P2-m comes from the mature plasma cells,
their precursors or other cells of the
lymphoid series. Studies of lymphoid
disease indicate that raised serum /32-m
can accompany a variety of benign and
malignant diseases involving B or T lym-
phocytes (Cooper & Spati, 1979). What-
ever the cell type or types contributing to
the production df /2-m, its origin is most
probably from the turnover ofHLA on cell
membranes, where /2-m forms the light
chain ofHLA (Cresswell et at., 1974).
In practice the measurement of serum
/32-m, at first presentation, would appear
to be useful for the stratification of mul-
tiple myeloma, especially when the creati-
nine level is normal. The frequency of a
renal impairment at first presentation
has been reported as 43/237 (18-1%) by
Woodruff et al. (1979), and 18% by
Alexanian et al. (1975) using criteria less
strict than ours.
High levels of serum P2-m at diagnosis
or after 12-18 months carry a poor prog-
nosis, and such levels are frequently
encountered in IgA and IgG myeloma
without an elevated serum creatinine
(Table II). Furthermore, serum /2-m
could well be a better reflection of the
tumour mass than the serum paraprotein
levels, and may offer a particular advan-
tage for the monitoring of Bence Jones
myelomatosis, as it is difficult to measure
the serum concentrations of light chains
accurately.
Severe acute infections do not neces-
sarily raise serum 32-m, which is inde-
pendent ofthe serum acute-phase reactive
protein response (Cooper & Spati, 1979).
This may account for the lack of rise of
P2-m in the terminal periods oflife ofthose
patients in Fig. 1 and 2 whose intercurrent
infectionwastheimmediate cause ofdeath.
Measurement of serum 32-m is simpler
and less problematical than existing stag-
ing systems and paraprotein estimations.
It may prove particularly applicable to
the stratification and subsequent monitor-
ing of patients with myelomatosis in the
multi-centre clinical trial.
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